![]() |
I hate biotech
check chart of NBIX to see why.
|
:eek:
|
ooooouuuuuuuuuuchhhhhhh.....that's why I stick to mutual funds now. learned my lesson after dumping a butt load into a tech stock on sept 8, 2001.
what happened? did the FDA reject something? hope you didn't take too much of a beating |
Yuck, what a drag.
Im still deep in NUVO and ALKS, heres hoping I don't have your luck. |
FDA rejected the long-acting dose of their insomnia drug. The short-acting dose was approved.
Big shock. Investors thought drug would either be approved outright, or approvable (will approve after resolve some final issues). No one imagined FDA would answer NON-approvable. Clinical data showed efficacy and no safety issues. Company said FDA letter indicated agency did not have enough time to review all data. This is hard to reconcile with a NON-approvable, but also makes no sense for management to misrepresent a letter that will be promptly examined by securities lawyers. So something weird has happened. Under an optimistic scenario, they satisfy FDA concerns and get approval in several months or a year. By then more insomnia drugs are on the market and PFE (who will market the drug) may be less committed to it. Under a pessimistic scenario, the long-acting dose is dead, PFE won't market the drug, and hard to see the company's future. Closed at $54 the day before. After the news was announced, the stock started trading pre-open at $30. Fell as people digested the news, was $25 by the time the market opened. Ended the day at $20. During the day, volume was roughly equal to the entire share count. Remarkable. But not that remarkable for biotech, unfortunately. |
All times are GMT -8. The time now is 08:23 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2025, vBulletin Solutions, Inc.
Search Engine Optimization by vBSEO 3.6.0
Copyright 2025 Pelican Parts, LLC - Posts may be archived for display on the Pelican Parts Website